HIV Vaccines: Intersections of Basic and Clinical Science
Apr 16–19, 2026 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers:
Penny L Moore, Marit van Gils, and Kevin O. Saunders
Livestream
In Person
On Demand
×
-
Apr 16–19, 2026 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers: Penny L Moore, Marit van Gils, and Kevin O. Saunders
Penny L Moore, PhD
University of the Witwatersrand and National Institute for Communicable Diseases
Marit van Gils, PhD
Amsterdam UMC
Kevin O. Saunders, PhD
Duke University
Available Formats:
Supported by:
Livestream
In Person
On Demand
***Meeting program subject to change.
Available Formats: = Livestream = In Person = On DemandThursday, April 16, 2026
Fundraising
Booking Function
Merchandise Options
Registration Options
Registration
4:00–8:00 PM
3rd Floor Foyer
Welcome Mixer
6:00–8:00 PM
3rd Floor Foyer
Friday, April 17, 2026
Breakfast
7:00–8:00 AM
Summit Gallery
Welcome Remarks (Joint)
8:00–8:10 AM
Colorado Ballroom
Keynote Address (Joint)
8:10–9:00 AM
Colorado Ballroom
* Marit van Gils, Amsterdam UMC
Session Chair
Session Chair
Alexandra Trkola, University of Zürich
Enabling Preventive and Therapeutic HIV Vaccine Research: The Swiss XbnAb Cohort
Enabling Preventive and Therapeutic HIV Vaccine Research: The Swiss XbnAb Cohort
Immune Interventions Interfacing HIV Prevention and Cure (Joint)
9:00–11:30 AM
Colorado Ballroom
* Mark Connors, NIAID, National Institutes of Health
Session Chair
Session Chair
Mauricio A. Martins, University of Florida
Promoting Persistent bNAb Expression in NHPs through AAV-Mediated Gene Transfer
Promoting Persistent bNAb Expression in NHPs through AAV-Mediated Gene Transfer
Devi SenGupta, Gilead Sciences, Inc.
Developing Combination Immunotherapy for HIV Cure
Developing Combination Immunotherapy for HIV Cure
Leonidas Stamatatos, Fred Hutchinson Cancer Research Center
Vaccination of PLWH, using 426C Derived Immunogens
Vaccination of PLWH, using 426C Derived Immunogens
Cristina Ceriani, Emory University
Short Talk: Influence of SIV Gag Vaccination on CD8⁺ T Cell Immunity and SIV Viral Dynamics
Short Talk: Influence of SIV Gag Vaccination on CD8⁺ T Cell Immunity and SIV Viral Dynamics
Nicolas M S Galvez Arriagada, Ragon Institute of Mass General, MIT and Harvard
Short Talk: Vectored Delivery of bNAbs Prevents Rebound of Clinical HIV Isolate During Antiretroviral Therapy Interruption
Short Talk: Vectored Delivery of bNAbs Prevents Rebound of Clinical HIV Isolate During Antiretroviral Therapy Interruption
Coffee Break
9:30–9:50 AM
3rd Floor Foyer
Award Recipient Acknowledgement
9:50–9:55 AM
Colorado Ballroom
On Own for Lunch
11:30–2:30 PM
Poster Setup
11:35–1:00 PM
Peaks 1 - 3
Poster Viewing
1:00–10:00 PM
Peaks 1 - 3
Symposia Spotlight 1: Driving CD4bs Antibodies Forward
2:30–4:30 PM
Colorado Ballroom
* Eunice Wambui Nduati, KEMRI, Wellcome Trust
Session Chair
Session Chair
* Richard T. Wyatt, The Scripps Research Institute
Session Chair
Session Chair
Matthew Clark, Duke University
Cross-Clade HIV-1 Neutralizing Antibodies With Characteristics of bNAbs, Including VRC01, in Children
Cross-Clade HIV-1 Neutralizing Antibodies With Characteristics of bNAbs, Including VRC01, in Children
Xuejun Chen, NIAID, National Institutes of Health
Three Sequential Escalating-Dose Immunizations Elicit VRC01-Class Antibody-Mediated Tier 2 HIV-1 Serum Neutralization in a Highly Stringent Mouse Model
Three Sequential Escalating-Dose Immunizations Elicit VRC01-Class Antibody-Mediated Tier 2 HIV-1 Serum Neutralization in a Highly Stringent Mouse Model
Ria Goswami, Weill Cornell Medicine
Germline-Targeting HIV SOSIP Trimer Immunizations Dampened Post-Rebound SHIV Loads in Infant Macaques
Germline-Targeting HIV SOSIP Trimer Immunizations Dampened Post-Rebound SHIV Loads in Infant Macaques
James A Counts, Duke University
Sequential Vaccination Elicits VH1-46 Class Orthologous Antibodies with Heterologous Reactivity and Neutralization Targeting the CD4-Binding Site In Rhesus Macaques
Sequential Vaccination Elicits VH1-46 Class Orthologous Antibodies with Heterologous Reactivity and Neutralization Targeting the CD4-Binding Site In Rhesus Macaques
Anna Romanov, Massachusetts Institute of Technology
DNA Origami Vaccines Program Antigen-Focused Germinal Centers
DNA Origami Vaccines Program Antigen-Focused Germinal Centers
Christopher A Cottrell, The Scripps Research Institute
Sequential Boosting with mRNA/LNP Immunogens Drives VRC01-Class Precursors B Cells To Acquire Key Mutations Allowing For Binding To Heterologous Wildtype HIV Env Trimers with the N276 Glycan
Sequential Boosting with mRNA/LNP Immunogens Drives VRC01-Class Precursors B Cells To Acquire Key Mutations Allowing For Binding To Heterologous Wildtype HIV Env Trimers with the N276 Glycan
Tom G Caniels, Amsterdam UMC
A Germline-Targeting Prime-Boost Regimen Drives Heterologous Neutralization Breadth of VRC01-class B Cells
A Germline-Targeting Prime-Boost Regimen Drives Heterologous Neutralization Breadth of VRC01-class B Cells
Jerome M Edwards, Fred Hutchinson Cancer Center
A Germline-Targeting Env-derived Immunogen Activates both VRC01- and CH235-class Naïve B Cells in a Phase 1 Clinical Trial
A Germline-Targeting Env-derived Immunogen Activates both VRC01- and CH235-class Naïve B Cells in a Phase 1 Clinical Trial
Coffee Available
4:30–5:00 PM
3rd Floor Foyer
Keeping up with the Changing HIV Envelope
5:00–7:00 PM
Colorado Ballroom
* Sampa Santra, Beth Israel Deaconess Medical Center, Harvard Medical School
Session Chair
Session Chair
Margaret E. Ackerman, Dartmouth College
Fc Effector Function in HIV Infection and Vaccination
Fc Effector Function in HIV Infection and Vaccination
Aime Marcel Simon Tongo Passo, Center for Research on Emerging and Re-Emerging Diseases (CREMER/IMPM)
Viral Diversity in Central Africa: Known and Unknowns
Viral Diversity in Central Africa: Known and Unknowns
Gnana Gnanakaran, Los Alamos National Laboratory
Conformation of HIV Env Trimer on Intact Virions
Conformation of HIV Env Trimer on Intact Virions
Ashwin N Skelly, University of Pennsylvania
Short Talk: Consistent Induction of V3-Glycan Broadly Neutralizing Antibodies by a Novel Two-Step Mechanism Informs Immunogen Design
Short Talk: Consistent Induction of V3-Glycan Broadly Neutralizing Antibodies by a Novel Two-Step Mechanism Informs Immunogen Design
Roma Broadberry, University of Wisconsin-Madison
Short Talk: Structural Characterization of Non-canonical Fusion Peptide-directed Broadly Neutralizing Antibodies from HIV-1 clade C
Short Talk: Structural Characterization of Non-canonical Fusion Peptide-directed Broadly Neutralizing Antibodies from HIV-1 clade C
Social Hour with Dinner
7:00–8:00 PM
Summit Gallery
Poster Session 1
7:30–10:00 PM
Peaks 1 - 3
Saturday, April 18, 2026
Breakfast
7:00–8:00 AM
Summit Gallery
The Vaccine Pipeline: Integrating Basic and Clinical Insights
8:00–11:00 AM
Colorado Ballroom
* Susan W Barnett, Gates Foundation
Session Chair
Session Chair
* Michael Farzan, Boston Children's Hospital; Harvard Medical School
Session Chair
Session Chair
Richard T. Wyatt, The Scripps Research Institute
Eliciting bNAbs to the Trimer Apex, Other Conserved Sites in NHPs
Eliciting bNAbs to the Trimer Apex, Other Conserved Sites in NHPs
Persephone Borrow, University of Oxford
Creating an Immune Environment Favorable for HIV-1 bnAb Induction
Creating an Immune Environment Favorable for HIV-1 bnAb Induction
Louis J. Picker, Oregon Health & Science University
Progress in CMV based Vaccines
Progress in CMV based Vaccines
Rui Kong, Emory University
Single-Cell-Derived Antibody Supernatant aNalysis (SCAN) Workflow for Vaccine Analysis
Single-Cell-Derived Antibody Supernatant aNalysis (SCAN) Workflow for Vaccine Analysis
Hlelolwenkosi Z Mlimi, University of KwaZulu-Natal - Nelson R. Mandela School of Medicine
Short Talk: Immunological and Genetic Features Associated with The Development of Broadly Neutralizing Antibodies and Fc-Effector Functions in People Living with HIV-1 Subtype C
Short Talk: Immunological and Genetic Features Associated with The Development of Broadly Neutralizing Antibodies and Fc-Effector Functions in People Living with HIV-1 Subtype C
Lily Zemelko, University of California - San Francisco (UCSF)
Short Talk: HIV DNA Therapeutic Vaccination Durably Boosts HIV-Specific CD8+ T Cell Magnitude and Proliferative Responses
Short Talk: HIV DNA Therapeutic Vaccination Durably Boosts HIV-Specific CD8+ T Cell Magnitude and Proliferative Responses
Coffee Break
9:00–9:20 AM
3rd Floor Foyer
LANL's HIV Sequence Database & Tips for Analyzing HIV Sequences + Q&A
11:00–12:00 PM
Colorado Ballroom
Poster Setup
11:00–1:00 PM
Peaks 1 - 3
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Peaks 1 - 3
Career Roundtable (Joint)
1:30–3:00 PM
Colorado Ballroom
Elena Vendrame, Gilead Sciences, Inc
Director
Director
Zoe R. Wallace, Immunocore
Principal Research Scientist I
Principal Research Scientist I
Kimmo Rantalainen, The Scripps Research Institute
Senior Scientist
Senior Scientist
Cesar A Boggiano, NIAID
Director
Director
Health Equity Panel (Joint) sponsored by The Burroughs Wellcome Fund
3:15–4:30 PM
Colorado Ballroom
Ole S Søgaard, Aarhus University Hospital
Marina F. Caskey, Rockefeller University
Devi SenGupta, Gilead Sciences, Inc.
Coffee Available
4:30–5:00 PM
3rd Floor Foyer
Targeting the Needle in the Haystack: Clinical Trials of Germline Targeting Immunogens
5:00–7:00 PM
Colorado Ballroom
* Cesar A Boggiano, NIAID
Session Chair
Session Chair
* Amelia Escolano, Wistar Institute
Session Chair
Session Chair
Kevin O Saunders, Duke University
Successful Germline-Targeting of CD4 Binding Site and V3-Glycan Antibodies in Phase I Trials
Successful Germline-Targeting of CD4 Binding Site and V3-Glycan Antibodies in Phase I Trials
Eunice Wambui Nduati, KEMRI, Wellcome Trust
Characterization of the B Cell Repertoire in African Populations to Inform HIV Vaccine Design
Characterization of the B Cell Repertoire in African Populations to Inform HIV Vaccine Design
Marit van Gils, Amsterdam UMC
Germline Targeting Immunogens in Human Clinical Trials; C101, C107, C110
Germline Targeting Immunogens in Human Clinical Trials; C101, C107, C110
Rachael Parks, Fred Hutchison Cancer Center
Short Talk: N332-GT5 Germline-Targeting Immunogen Elicits BG18-bnAb Precursors in a Phase I, Human Clinical Trial (HVTN 144)
Short Talk: N332-GT5 Germline-Targeting Immunogen Elicits BG18-bnAb Precursors in a Phase I, Human Clinical Trial (HVTN 144)
Catarina Mendes Silva, Amsterdam UMC
Short Talk: Proof-of-Concept Induction of HIV Broadly Neutralizing Antibody Lineages by Vaccination In Humans
Short Talk: Proof-of-Concept Induction of HIV Broadly Neutralizing Antibody Lineages by Vaccination In Humans
Social Hour with Dinner
7:00–8:00 PM
Summit Gallery
Poster Session 2
7:30–10:00 PM
Peaks 1 - 3
Sunday, April 19, 2026
Breakfast
7:00–8:00 AM
Summit Gallery
Looking to the Future: New Tools, Platforms and Delivery Systems
8:00–11:00 AM
Colorado Ballroom
* Sudhir P Kasturi, Emory University
Session Chair
Session Chair
* Barbara K Felber, NCI, National Institutes of Health
Session Chair
Session Chair
Mangala Rao, USMHRP, Walter Reed Army Institute of Research
Remote Presentation: ALFQ: A Robust Adjuvant for Preclinical and Clinical Studies
Remote Presentation: ALFQ: A Robust Adjuvant for Preclinical and Clinical Studies
Eric A. Appel, Stanford University
Injectable Hydrogel Depot Technologies for Sustained Delivery of Vaccines
Injectable Hydrogel Depot Technologies for Sustained Delivery of Vaccines
Rory Henderson, Duke University
AI Guided Immunogen Design: A New Framework for HIV Vaccine Development
AI Guided Immunogen Design: A New Framework for HIV Vaccine Development
Nitesh Mishra, The Scripps Research Institute
Short Talk: De Novo, Machine Learning Enabled Discovery of Broadly Neutralizing Unmutated Human Antibodies Against HIV-1
Short Talk: De Novo, Machine Learning Enabled Discovery of Broadly Neutralizing Unmutated Human Antibodies Against HIV-1
Hongying Duan, NIH/VRC
Short Talk: Vaccine Elicitation of HIV-1 Cross-strain Neutralizing Antibodies Against Both V2 Apex and Fusion Peptide in Rhesus Macaques
Short Talk: Vaccine Elicitation of HIV-1 Cross-strain Neutralizing Antibodies Against Both V2 Apex and Fusion Peptide in Rhesus Macaques
Austin Kriews, The Wistar Institute
Short Talk: Exposure to the HIV-1 gp41 Base Redirects the Specificity of Broadly Neutralizing Antibody Lineages
Short Talk: Exposure to the HIV-1 gp41 Base Redirects the Specificity of Broadly Neutralizing Antibody Lineages
Kshitij Wagh, Duke University
Short Talk: Induction of V2-apex Broadly-Neutralizing Antibodies by Signature-Based Prime and Boost mRNA Immunogens in Rhesus Macaques
Short Talk: Induction of V2-apex Broadly-Neutralizing Antibodies by Signature-Based Prime and Boost mRNA Immunogens in Rhesus Macaques
Coffee Break
9:00–9:20 AM
3rd Floor Foyer
LANL's HIV Immunology Database & CATNAP Tool + Q&A
11:00–12:00 PM
Colorado Ballroom
On Own for Lunch
11:00–2:30 PM
Panel: From Vision to Viability - Navigating the Funding Landscape for Future HIV Research (Joint)
1:15–2:15 PM
Colorado Ballroom
Pervin Anklesaria, Bill & Melinda Gates Foundation
Vasudev Rao, National Institute of Mental Health
Elisabet Caler, NHLBI, National Institutes of Health
Diane M. Lawrence, NIAID, National Institutes of Health
Andrea Gramatica, amfAR
Cesar A Boggiano, NIAID
Symposia Spotlight 2: Looking Beyond the CD4bs
2:30–4:30 PM
Colorado Ballroom
* Wilton B Williams, Duke University School of Medicine
Session Chair
Session Chair
* Katharine J Bar, University of Pennsylvania
Session Chair
Session Chair
Fabian-Alexander Schleich, Karolinska Institutet
Vaccination Of Nonhuman Primates Elicits a Broadly Neutralizing Antibody Lineage Targeting a Quaternary Epitope on the HIV-1 Env trimer
Vaccination Of Nonhuman Primates Elicits a Broadly Neutralizing Antibody Lineage Targeting a Quaternary Epitope on the HIV-1 Env trimer
Joshua Carter, Stanford University
Minimally Mutated Silent Face Antibodies Enable Germline-targeted Vaccine Design for the Silent Face Epitope
Minimally Mutated Silent Face Antibodies Enable Germline-targeted Vaccine Design for the Silent Face Epitope
Rumi Habib, University of Pennsylvania
Env-Antibody Coevolution Identifies B Cell Priming as the Principal Bottleneck to HIV-1 V2 Apex Broadly Neutralizing Antibody Development
Env-Antibody Coevolution Identifies B Cell Priming as the Principal Bottleneck to HIV-1 V2 Apex Broadly Neutralizing Antibody Development
Severin Coleon, Duke Human Vaccine Institute (DHVI)
Priming Diverse V2 Apex Antibodies with Unique HCDR3 Motifs Using Germline-Targeting HIV-1 Env Ferritin Nanoparticles in Rhesus Macaques
Priming Diverse V2 Apex Antibodies with Unique HCDR3 Motifs Using Germline-Targeting HIV-1 Env Ferritin Nanoparticles in Rhesus Macaques
Lorie Marchitto, University of Pennsylvania
Enhanced B Cell Priming Leads to Rapid Induction of Broadly Neutralizing HIV-1 Apex Antibodies
Enhanced B Cell Priming Leads to Rapid Induction of Broadly Neutralizing HIV-1 Apex Antibodies
Tianling Ou, Broad Institute
Sequential Immunogens Drive Affinity Maturation of HIV-1 V2-Apex Broadly Neutralizing Antibody Precursors
Sequential Immunogens Drive Affinity Maturation of HIV-1 V2-Apex Broadly Neutralizing Antibody Precursors
Kevin Wiehe, Duke University
Reliable Elicitation of Broadly Neutralizing Antibodies in the Serum of V3 Glycan bnAb UCA Knock-in Mice Immunized with a 4-Immunogen Vaccine Regimen
Reliable Elicitation of Broadly Neutralizing Antibodies in the Serum of V3 Glycan bnAb UCA Knock-in Mice Immunized with a 4-Immunogen Vaccine Regimen
Jon Steichen, The Scripps Research Institute
Germline-Targeting Vaccination Elicits HIV Broadly Neutralizing Antibodies In Nonhuman Primates
Germline-Targeting Vaccination Elicits HIV Broadly Neutralizing Antibodies In Nonhuman Primates
Coffee Available
4:30–5:00 PM
3rd Floor Foyer
B Cell Responses and Broadly-Neutralizing Antibodies: Trials and Tribulations (Joint)
5:00–6:30 PM
Colorado Ballroom
* Kevin O Saunders, Duke University
Session Chair
Session Chair
Marina F. Caskey, Rockefeller University
Combined Immunotherapy with IL-15 Agonists and Broadly-Neutralizing Antibodies
Combined Immunotherapy with IL-15 Agonists and Broadly-Neutralizing Antibodies
Paula M Cannon, University of Southern California, Keck School of Medicine
Engineering B Cells as in vivo bnAb Factories
Engineering B Cells as in vivo bnAb Factories
William Schief, Moderna, Scripps, and IAVI
Combining Germline Targeting Approaches Across Diverse bNAb Epitopes
Combining Germline Targeting Approaches Across Diverse bNAb Epitopes
Meeting Wrap-Up: Outcomes and Future Directions (Joint)
6:30–6:45 PM
Colorado Ballroom
* Kevin O Saunders, Duke University
Social Hour with Dinner
6:45–7:45 PM
Summit Gallery
Cash Bar
7:45–8:45 PM
Summit Gallery
Monday, April 20, 2026
Departure
12:00–11:59 PM
Subscribe for Updates